Oncology Institute (TOIIW) Consolidated Net Income (2020 - 2026)

Oncology Institute has reported Consolidated Net Income for 7 years, with the latest figure at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 87.28% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$43.5 million (up 32.39% YoY), and the FY2025 full-year result was -$60.6 million, up 6.27% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$2.5 million, up from -$7.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was $19.3 million in Q1 2022, with the low at -$30.0 million in Q1 2023.
• Historically, Consolidated Net Income has averaged -$12.4 million across 5 years, with a median of -$16.1 million in 2024.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 2036.35% — and 2023, when it slumped 551.42%.
• Oncology Institute's Consolidated Net Income stood at -$11.0 million in 2022, then plunged by 70.38% to -$18.8 million in 2023, then increased by 29.71% to -$13.2 million in 2024, then jumped by 43.04% to -$7.5 million in 2025, then soared by 66.81% to -$2.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$2.5 million (Q1 2026), -$7.5 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.